Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Accolade (Nasdaq: ACCD) announced a partnership with WellRight, a leader in corporate wellness programs, to enhance its partner ecosystem. This collaboration aims to address employee health benefits, retention, and engagement, aligning with the current demands of employers. WellRight's platform incorporates data from various sources to create personalized wellness plans. The partnership aims to deliver improved health outcomes through a comprehensive approach to employee well-being, emphasizing the importance of personalized healthcare solutions.
Accolade, Inc. (NASDAQ: ACCD) reported a significant revenue increase of 99% for the fiscal second quarter ended August 31, 2021, reaching $73.3 million compared to $36.8 million in the same period last year. Despite this growth, the company faced a net loss of $62.4 million, a 306% increase from the previous year. Accolade launched its new Personalized Healthcare category and introduced two solutions, Accolade One and Accolade Care, aimed at enhancing value-based care. The acquisition of HealthReveal will further bolster its technology for personalized chronic care.
Summary not available.
Accolade, Inc. (Nasdaq: ACCD) launched a new healthcare category called Personalized Healthcare on Sept. 21, 2021, during its Evolve21 event. This initiative aims to enhance value-based care through three core pillars: Personal, Data driven, and Value based. New solutions include Accolade One and Accolade Care, focusing on integrated healthcare delivery. CEO Rajeev Singh emphasized the importance of human relationships in healthcare, addressing employee demands for better healthcare experiences. A SHRM survey highlighted that healthcare influences job change decisions for over half of U.S. employees.
Accolade, Inc. (Nasdaq: ACCD) will announce key updates during its annual customer event, Evolve21, on September 21, 2021. The event will be held virtually from September 21-23, 2021, and will feature an executive keynote session from 8:00am-10:00am PT, followed by a Q&A session from 10:15am-11:00am PT. Key speakers include CEO Rajeev Singh, SVP Umair Khan, and Chief Innovation Officer Mike Hilton. All sessions can be accessed through their official webcasts.
Accolade, Inc. (NASDAQ: ACCD) will announce its fiscal Q2 2022 financial results on October 7, 2021, post-market close. A conference call will follow at 4:30 p.m. E.T. for result discussions. Investors can join via phone or a live audio webcast available at their investor relations site. Accolade specializes in personalized health and benefits solutions aimed at improving health outcomes and reducing care costs for millions. The company maintains high consumer satisfaction ratings, exceeding 90%. For further details, investors may contact their investor relations team.
Accolade, Inc. (NASDAQ: ACCD) will participate in two upcoming investor conferences: the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 8:45 a.m. E.T. and Baird’s 2021 Global Healthcare Conference on September 15, 2021, at 9:05 a.m. E.T. The company focuses on personalized health and benefits solutions, aiding individuals in managing healthcare complexities. Accolade boasts over 90% consumer satisfaction and aims to enhance health outcomes while reducing care costs. More details can be found at accolade.com.
Accolade, Inc. (NASDAQ: ACCD) will attend the 41st Annual Canaccord Genuity Growth Conference, featuring a presentation on August 12, 2021, at 11:00 a.m. E.T. An audio webcast and related materials will be accessible on their investor relations website. Accolade specializes in personalized health and benefits solutions, aiding individuals and employers in navigating healthcare complexities with a focus on lowering costs and improving outcomes. The company enjoys consumer satisfaction ratings exceeding 90%. For more information, visit their website or social media channels.
Accolade, Inc. reported a fiscal first quarter 2022 revenue of $59.5 million, a substantial 66% increase from $35.9 million in the same quarter of 2021. The company raised its fiscal year 2022 revenue guidance to $300 million - $305 million, reflecting a 78% increase year-over-year. However, the company also reported a net loss of $48.7 million, a 249% increase from the previous year's $14 million loss. Adjusted EBITDA was $(12.8) million, worsening by 36%. CEO Rajeev Singh highlighted strategic acquisitions and integrated care capabilities as keys to future growth.
Accolade, Inc. (NASDAQ: ACCD) announced the release of its fiscal first quarter 2022 financial results scheduled for July 8, 2021, post-market close. A conference call will be held at 4:30 p.m. E.T. to discuss these results, accessible via phone or a live audio webcast. Accolade focuses on personalized health and benefits solutions, aiming to empower individuals to achieve better health outcomes and reduce healthcare costs. The company has maintained high consumer satisfaction ratings over 90 percent.